Exact Sciences to Sell to Abbott for $105 per Share in Cash
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Source: Globenewswire
- Legal Investigation Initiated: Halper Sadeh LLC is investigating Exact Sciences Corporation's sale to Abbott for $105 per share in cash, potentially indicating violations of federal securities laws and breaches of fiduciary duties to shareholders, which could impact shareholder rights and the legality of the transaction.
- Shareholder Rights Protection: The law firm encourages Exact Sciences shareholders to reach out to understand their legal rights and options, emphasizing the importance of shareholder interests and potentially leading to a reevaluation of the transaction terms.
- Potential Compensation Claims: Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and information, demonstrating a proactive stance in protecting shareholder rights, which could influence the final outcome of the transaction.
- Legal Fee Arrangement: The firm commits to handling the case on a contingent fee basis, meaning shareholders will not incur upfront legal costs, thereby reducing the financial burden on shareholders and encouraging greater participation in legal actions.
Analyst Views on EXAS
Wall Street analysts forecast EXAS stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXAS is 95.50 USD with a low forecast of 50.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
21 Analyst Rating
4 Buy
17 Hold
0 Sell
Hold
Current: 102.340
Low
50.00
Averages
95.50
High
105.00
Current: 102.340
Low
50.00
Averages
95.50
High
105.00
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
